The effect of ketamine on anhedonia: improvements in dimensions of anticipatory, consummatory, and motivation-related reward deficits

Jasrai, Ashitija; Kim, Haeun; Nasri, Flora; Ceban, Felicia; Lui, Leanna M.W.; Rosenblat, Joshua D.; Vinberg, Maj; Ho, Roger; McIntyre, Roger S.

doi:10.1007/s00213-022-06105-9

Cited by 27 publications

(19 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Agomelatine is a novel antidepressant as well as a potent agonist of melatonin (MT), MT1 and MT2 receptor types and an antagonist of the serotonin (5HT) 68 . Vortioxetine is also a novel antidepressant capable of improving depressive and cognitive symptoms associated with major depressive disorder (MDD) 69 , while Ketamine is a rapid-acting and novel therapeutic treatment for treatment-resistant depression, which has also been demonstrated to attenuate symptoms of anhedonia 70 . Therefore we highly propose the testing of the in vitro antiviral activity of these novel antidepressants against COVID-19 in future studies.…”

Section: Discussionmentioning

confidence: 99%

Robust antiviral activity of commonly prescribed antidepressants against emerging coronaviruses: in vitro and in silico drug repurposing studies

Kutkat

Moatasim

Al‐Karmalawy

et al. 2022

Sci Rep

View full text Add to dashboard Cite

During the current coronavirus disease 2019 (COVID-19) pandemic, symptoms of depression are commonly documented among both symptomatic and asymptomatic quarantined COVID-19 patients. Despite that many of the FDA-approved drugs have been showed anti-SARS-CoV-2 activity in vitro and remarkable efficacy against COVID-19 in clinical trials, no pharmaceutical products have yet been declared to be fully effective for treating COVID-19. Antidepressants comprise five major drug classes for the treatment of depression, neuralgia, migraine prophylaxis, and eating disorders which are frequently reported symptoms in COVID-19 patients. Herein, the efficacy of eight frequently prescribed FDA-approved antidepressants on the inhibition of both SARS-CoV-2 and MERS-CoV was assessed. Additionally, the in vitro anti-SARS-CoV-2 and anti-MERS-CoV activities were evaluated. Furthermore, molecular docking studies have been performed for these drugs against the spike (S) and main protease (Mpro) pockets of both SARS-CoV-2 and MERS-CoV. Results showed that Amitriptyline, Imipramine, Paroxetine, and Sertraline had potential anti-viral activities. Our findings suggested that the aforementioned drugs deserve more in vitro and in vivo studies targeting COVID-19 especially for those patients suffering from depression.

show abstract

Section: Discussionmentioning

confidence: 99%

Robust antiviral activity of commonly prescribed antidepressants against emerging coronaviruses: in vitro and in silico drug repurposing studies

Kutkat

Moatasim

Al‐Karmalawy

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Investigations into ketamine's use as a prophylactic, using mice, had limitations because they did not analyze anhedonia, which is a key feature in translational models of depression (Brachman et al, 2016;Mastrodonato et al, 2020). Although it is important to highlight that ketamine has demonstrated positive effects in reducing anhedonia in patients and some animal models of depression when this symptom is already present (Nogo et al, 2022).…”

Section: Discussionmentioning

confidence: 99%

Prophylactic action of ayahuasca in a non-human primate model of depressive-like behavior

Grilo

Sousa

Mendonça

et al. 2022

Front. Behav. Neurosci.

View full text Add to dashboard Cite

Observational studies of long-term users of ayahuasca, an Amazonian psychedelic brew, suggest an increase in resilience via improvements in emotion and cognition. Ayahuasca has also demonstrated clinical antidepressant effects in human and animal studies; however, its potential prophylactic action in depression has not been previously studied. Therefore, this experimental study sought to evaluate the potential prophylactic effects of repeated and long-term ayahuasca use, via the modulation of resilience, in a non-human primate animal model, Callithrix jacchus, subjected to a protocol for induction of depressive-like behavior. For the formation of the study groups, some juvenile marmosets were kept in their family groups (GF = 7), while for the two experimental groups, the animals were removed from the family and kept socially isolated. Then, part of the isolated animals made up the group in which ayahuasca was administered (AG, n = 6), while for others, no intervention was made (IG, n = 5). AG animals took ayahuasca (1.67 mL/300g body weight) at weeks 4 (before isolation), 8, and 12 (during isolation) of the study. More adaptive stress response was observed for the AG when compared to the IG. The AG showed higher cortisol reactivity and fecal cortisol levels than IG, while both measures were similar to FG. Moreover, AG animals showed no signs of anhedonia and no increase in chronic stress-related behaviors, which were expressed by the IG. Thus, ayahuasca seems to promote the expression of resilient responses, indicating a prophylactic action, buffering the emergence of depressive-like behaviors and cortisol alterations associated with major depression. These results are encouraging for further research on the prophylactic use of psychedelics to prevent psychopathologies associated with chronic stress.

show abstract

“…In a pilot study, Pettoruso et al successfully treated patients with cocaine use disorder with repetitive transcranial magnetic stimulation to improve anhedonia ( 87 ). Interestingly, the NMDA receptor antagonist ketamine which has shown remarkable preliminary results in the treatment of SUDs ( 88 , 89 ), also seems to have significant anti-anhedonic effects ( 90 , 91 ).…”

Section: Discussionmentioning

confidence: 99%

Negative symptoms in alcohol use disorder: A pilot study applying the two-factor model of negative symptoms to patients with alcohol use disorder

Buschner¹,

Dürsteler²,

Fischli³

et al. 2022

Front. Psychiatry

View full text Add to dashboard Cite

Background and aimsAlcohol Use Disorder (AUD) is characterized by a reduction in goal-directed behavior, with alcohol use taking precedence over other areas of life. These features in AUD resemble negative symptoms in schizophrenia, especially the reduction in motivation and pleasure (MAP). Given the clinical similarities of negative symptoms across diagnostic categories, it comes as a surprise that there are few investigations on negative symptoms in alcohol and other substance use disorders. To our knowledge, our study is the first to assess negative symptoms in AUD based on a two-factorial approach, and to investigate the interrelation of these dimensions with the severity of AUD, and alcohol craving.Materials and methodsWe examined a sample of 42 patients with AUD at the Psychiatric University Hospital in Zurich. Participants provided self-report and interview-based measures of the severity of AUD, negative symptoms, and alcohol craving. Finally, we used data from the electronic health records of the patients.ResultsPatients with AUD show negative symptoms to a similar extent as patients with schizophrenia or bipolar disorder. We found a positive correlation between the extent of impairment within the MAP factor and overall severity of AUD. Furthermore, MAP negative symptoms were correlated with alcohol craving. In a linear regression, negative symptoms predicted alcohol craving whereas depression did not.SummaryNegative symptoms as conceptualized for schizophrenia are prevalent in patients with AUD and associated with the severity of AUD. More specifically, severity of AUD correlates with diminished motivation and pleasure, highlighting the importance of disturbances in motivational functions in AUD. This is further supported by the correlation between negative symptoms and craving, a hallmark of AUD. Taken together, our findings suggest that negative symptoms might be a highly relevant but hitherto often neglected therapeutic target in AUD.

show abstract

The effect of ketamine on anhedonia: improvements in dimensions of anticipatory, consummatory, and motivation-related reward deficits

Cited by 27 publications

References 82 publications

Robust antiviral activity of commonly prescribed antidepressants against emerging coronaviruses: in vitro and in silico drug repurposing studies

Robust antiviral activity of commonly prescribed antidepressants against emerging coronaviruses: in vitro and in silico drug repurposing studies

Prophylactic action of ayahuasca in a non-human primate model of depressive-like behavior

Negative symptoms in alcohol use disorder: A pilot study applying the two-factor model of negative symptoms to patients with alcohol use disorder

Contact Info

Product

Resources

About